Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations Authors Ylmaz N , Bastemir M Received 27 November 2025 Accepted for publication 13 January 2026 Published 30 January 2026 Volume 2026:19 584175 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Halis Akturk Nimet Ylmaz, 1 Mehmet Bastemir 2 1 Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey
Dosage schedules vary depending on concentration and formulation
May support overall bone quality beyond just density measurements
No, products in the FBX GLP-1 Support range are not medications
4.1 Liu dng Glutathione lm trng da (ng ung) Trong 3 thng u, bn c th ung khong 1000mg-2000mg Glutathione, sau gim xung cn 500mg mi ngy
GLP-1RAs play a key role in regulating the response to inflammation of the endothelium
